Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study suggests. Peripheral arterial disease is a difficult-to-treat problem ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...